Anti-androgens such as Spironolactone can potentially be beneficial for reversing hair loss but it is rarely prescribed for male patients due to systemic and feminizing side effects that could be serious even if the medication is applied topically. This may soon change.
Kintor Pharmaceutical is currently developing a new topical treatment for hair loss called GT20029 and has received approval from local authority to proceed with clinical trials. If the trials are successful, GT20029 will be the world’s first topical androgen receptor inhibitor compound that is developed using Kintor’s proprietary Proteolysis Targeting Chimera (PROTAC) platform.
Preclinical studies for GT20029 suggest that this topical formula is superior to other products on the market because it does not cause systemic absorption in our body and hence fewer side effects for the patient while accomplishing the same or higher efficacy as an anti-androgen treatment for hair loss even for male patients.
See article below to learn more.
Kintor Pharmaceutical Announces AR-PROTAC (GT20029) Approved for Acne and Androgenic Alopecia Clinical Trials in China
This is a Hasson & Wong sponsored content - presently the #1 Top Ranked Hair Clinic in Canada, proudly Canadian and famous worldwide.
Schedule a FREE consultation to see if you are a good candidate for the latest in hair restoration technologies.